Serum carboxypeptidaseA4 levels predict liver metastasis in colorectal carcinoma.
Serum carboxypeptidaseA4 levels predict liver metastasis in colorectal carcinoma.
复制标题
DOI：
10.18632/oncotarget.12798
复制
发表时间：
2016-11-29
期刊：
影响因子：
--
通讯作者：
Sun D
中科院分区：
文献类型：
--
作者：
Sun L;Guo C;Burnett J;Yang Z;Ran Y;Sun D
肝转移是结直肠癌（CRC）最关键的预后因素，早期发现CRC肝转移可以显着改善癌症患者的预后。在本研究中，我们检测了 CRC 样本中的 CPA4 水平，并评估了血清 CPA4 作为预测 CRC 肝转移的生物标志物的潜力。在68.4%（130/190）的结直肠癌组织中观察到CPA4阳性，并且与浸润深度、淋巴结转移、远处转移和分期显着相关。此外，CPA4 高表达与较差的总生存期相关，并且是 CRC 患者的独立预后标志物。在CRC血清样本中，CRC-M1(S)患者的血清CPA4浓度(3717.89±375.98 pg/mL)显着高于CRC-M1(H)患者(3692.12±261.51 pg/mL)、无肝转移的CRC患者(2480.47±507.90 pg/mL)或健康对照(2183.7 ± 621.7 pg/mL) (P < 0.05)。此外，高CPA4浓度与CRC患者的远处转移、淋巴结受累、分期和较差的总生存率显着相关。 Logistic回归分析显示，血清CPA4水平和淋巴结转移情况是预测CRC肝转移的重要参数。在留一交叉验证中，这两种标记物对肝转移检测具有敏感性 (90.0%) 和特异性 (93.8%)。此外，这种组合可以在独立测试集中正确分类 50 名异时性肝转移 CRC 患者中的 49 例。因此，我们的结果表明CPA4与CRC肝转移密切相关，血清CPA4浓度结合淋巴结受累情况可作为结直肠癌肝转移的准确预测因子。
Hepatic metastasis is the most critical prognostic factor for colorectal cancer (CRC), and early detection of CRC liver metastasis can significantly improve cancer patient outcomes. In this study, we examined the levels of CPA4 in CRC samples, and assessed the potential of serum CPA4 as a biomarker for predicting CRC liver metastasis. CPA4 positivity was observed in 68.4% (130/190) colorectal cancer tissues, and significantly correlated with Depth of invasion, Lymph node metastasis, Distant metastasis and Stage. In addition, high CPA4 expression was associated with poor overall survival, and was an independent prognostic marker in patients with CRC. In CRC serum samples, serum CPA4 concentrations in CRC-M1(S) patients (3717.89 ± 375.98 pg/mL) were significantly increased as compared to in CRC-M1(H) patients (3692.12 ± 261.51 pg/mL), CRC patients without liver metastasis (2480.47 ± 507.90 pg/mL) or healthy controls (2183.7 ± 621.7 pg/mL) (P < 0.05). Furthermore, high CPA4 concentration was significantly correlated with Distant metastasis, Lymph node involvement, Stage and poor overall survival of the patients with CRC. Logistic regression analysis revealed that serum CPA4 level and Lymph node metastasis were the significant parameters for predicting CRC liver metastasis. In leave-one-out-cross-validation, these two markers resulted in sensitivity (90.0%) and specificity (93.8%) for hepatic metastasis detection. Moreover, this combination could correctly classify 49 cases of the 50 CRC patients with heterochronous liver metastasis in an independent test set. Therefore, our results suggest that CPA4 is closely associated with CRC liver metastasis, and serum CPA4 concentration combined with lymph node involvement may be used as accurate predictors of liver metastasis in colorectal cancer.